Starling Oncology, Inc.
STLN Nasdaq· Services-Offices & Clinics Of Doctors Of Medicine
Last close · Oct 27, 2026
$6.59
KIRA · Stoqly’s AI analyst, in plain words
- Starling Oncology, Inc. had $503M of revenue in fiscal 2025, up 27.8% on the year before. Over five years, revenue changed +21.8% a year on average.
- Its operating margin was −7.2%, up 8.1 pts: of every 100 in sales, about −7 is left after running the business.
- Starling Oncology, Inc. lost $60.6M in fiscal 2025.
- Free cash flow was −$27.8M in fiscal 2025, −5.5% of revenue.
- Starling Oncology, Inc. owes $43.9M more than it holds in cash.
Market cap
$679M
P/E
—
Revenue
$503M
Net income
−$60.6M
Free cash flow
−$27.8M
Operating margin
−7.2%
Starling Oncology, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+27.8%
Yes. Sales grew 27.8% last year.
Does it make a profit?
−12.1%
No. It lost money last year.
Does profit turn into cash?
−5.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Starling Oncology, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- Starling Oncology, Inc.
- CIK
- 0001799191
Starling Oncology, Inc. · STLN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $203M | $252M | $324M | $393M | $503M |
| Revenue growth | 8.3% | 24.4% | 28.4% | 21.3% | 27.8% |
| Net interest income | −$0.3M | −$4.1M | −$6.8M | — | — |
| Operating margin | −22.6% | −32.5% | −23.8% | −15.3% | −7.2% |
| Net income | −$10.9M | $0.2M | −$83.1M | −$64.7M | −$60.6M |
| Net margin | −5.4% | 0.1% | −25.6% | −16.4% | −12.1% |
| Diluted EPS | −$0.16 | −$0.21 | −$0.92 | −$0.71 | −$0.54 |
| Cash | |||||
| Cash from operations | −$32.7M | −$61.8M | −$36.3M | −$26.5M | −$24.6M |
| Capital expenditure | $2.8M | $5.5M | $4.6M | $3.8M | $3.2M |
| Free cash flow | −$35.5M | −$67.3M | −$40.9M | −$30.3M | −$27.8M |
| FCF margin | −17.5% | −26.6% | −12.6% | −7.7% | −5.5% |
| Share buybacks | $0.0M | $9.0M | $1.0M | $0.0M | — |
| Share count change | 12.0% | 21.7% | −8.5% | 1.8% | 23.1% |
| Debt and strength | |||||
| Cash and short-term investments | $115M | $73.8M | $82.9M | $49.7M | $33.6M |
| Debt incl. finance leases | $0.4M | $80.9M | $87.0M | $93.2M | $77.5M |
| Shareholders' equity | $104M | $123M | $57.0M | $3.6M | −$15.7M |
| Current ratio | 5.2x | 4.4x | 4.1x | 2.2x | 1.6x |
| Interest coverage | −143.3x | — | −11.4x | −8.0x | −3.2x |
| Returns and quality | |||||
| Return on capital | — | −49.8% | −99.8% | −100.9% | −101.4% |
| Return on equity | −16.5% | 0.1% | −92.2% | −213.4% | — |
| Return on tangible equity | −17.9% | 0.1% | −212.8% | — | — |
| Piotroski F-score | 3 | 2 | 3 | 3 | 4 |
| Altman Z'' | 2.6 | 0.6 | −0.9 | −4.0 | −5.3 |
Insiders bought, 12 months
$2.7M
1 insider
Insiders sold, 12 months
$2.8M
5 insiders
Of sales under plans
91%
$2.6M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Starling Oncology, Inc. · STLN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.59 a share, the company is worth $679M.
Source: SEC EDGAR XBRL filings (CIK 0001799191). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.